AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

AbbVie (NYSE:ABBV) said it has received FDA approval for the intravenous antibiotic treatment Emblaveo, which was co-developed with Pfizer (NYSE:PFE). The FDA approved Emblaveo, a combination of ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI), including those caused by Gram-negative bacteria that represent a ...

Pfizer’s Emblaveo has been approved in the EU with a first-in-class indication in multidrug-resistant (MDR) infections. The drug – a combination of beta-lactam antibiotic aztreonam with beta ...

The healthcare sector, too, has seen advances with AbbVie's EMBLAVEO™ gaining FDA approval for a combination antibiotic, and the European Medicines Agency recommending its arthritis treatment ...

NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the treatment of adults with complicated intra-abdominal infections (cIAI) with ...

The healthcare sector, too, has seen advances with AbbVie's EMBLAVEO™ gaining FDA approval for a combination antibiotic, and the European Medicines Agency recommending its arthritis treatment, RINVOQ® ...